SOM Stock Overview
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
SomnoMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.49 |
| 52 Week High | AU$0.52 |
| 52 Week Low | AU$0.19 |
| Beta | 1.32 |
| 1 Month Change | 15.29% |
| 3 Month Change | 50.77% |
| 1 Year Change | 8.89% |
| 3 Year Change | -77.73% |
| 5 Year Change | -83.16% |
| Change since IPO | -94.79% |
Recent News & Updates
Recent updates
SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 02
Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet
Oct 16SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Jul 15SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth
May 31SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 15SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?
Mar 04Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)
Dec 21SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks
Sep 02Is SomnoMed (ASX:SOM) Using Too Much Debt?
Jun 19It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year
Nov 18SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?
Sep 27Is SomnoMed (ASX:SOM) Using Debt Sensibly?
May 10Is SomnoMed (ASX:SOM) Using Debt Sensibly?
Oct 26Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?
May 12Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?
Mar 02Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?
Feb 01
Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?
Dec 28Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?
Dec 01Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)
Jul 28SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings
Jul 14Shareholder Returns
| SOM | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 15.3% | 1.3% | 0.1% |
| 1Y | 8.9% | 6.3% | 9.8% |
Return vs Industry: SOM exceeded the Australian Medical Equipment industry which returned 6.3% over the past year.
Return vs Market: SOM matched the Australian Market which returned 9.8% over the past year.
Price Volatility
| SOM volatility | |
|---|---|
| SOM Average Weekly Movement | 17.5% |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 2.9% |
Stable Share Price: SOM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: SOM's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Amrita Blickstead | somnomed.com/au/ |
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances.
SomnoMed Limited Fundamentals Summary
| SOM fundamental statistics | |
|---|---|
| Market cap | AU$100.49m |
| Earnings (TTM) | -AU$12.24m |
| Revenue (TTM) | AU$91.65m |
1.2x
P/S Ratio-8.7x
P/E RatioIs SOM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOM income statement (TTM) | |
|---|---|
| Revenue | AU$91.65m |
| Cost of Revenue | AU$36.52m |
| Gross Profit | AU$55.13m |
| Other Expenses | AU$67.37m |
| Earnings | -AU$12.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 60.15% |
| Net Profit Margin | -13.36% |
| Debt/Equity Ratio | 2.3% |
How did SOM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 07:35 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SomnoMed Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Meichelboeck | Select Equities Pty Ltd |
| Dr Storey | Wilsons Advisory and Stockbroking Ltd. |